Trump’s cuts to foreign aid are undermining the Ebola response, insiders say

• by Daniel Payne

• May 19, 2026

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.

• by Kerri Miller

• May 11, 2026

• 6 min

Genomic epidemiology of the 2025 mpox epidemic in Sierra Leone

• by Allan K. O. Campbell, John Demby Sandi, Ifeanyi F. Omah, Martin Faye, Edyth Parker, Taylor Brock-Fisher, Crystal M. Gigante, Vidalyn Folorunso, Mohamed Saio Kamara, Anu Jegede Williams, Mouhamed Kane, Tiangay Mariama Patience Sallay Kallon, Julian Campbell, Kadiatu Salmata Sesay, Sia Mani, Choe Miller, Naomi Daniel Sesay, Francis Baimba, Mignane Ndiaye, Roberta Lansana, Ibrahim Umaru Fofanah, Simon Ruhweza, Zein Souma, Amanda Kargbo, Komba Koninga, Alie Tia, Jone Ngobeh, Foday Thoronka, Alusine Fofanah, Al Ozonoff, Colby Wilkason, Danny Park, Christopher Tomkins-Tinch, Marietou F. Paye, Christopher Shin, Ian Baudi, Brendan Blumenstiel, Patrick Varilly, Ivan Specht, Ben Fry, Karlie Zhao, Paul Cronan, Ellory Laning, Oludayo Oluwaseyi Ope-ewe, Ayotunde Elijah Sijuwola, Femi Saibu, Harouna Soumare, Ebenezer Kehinde Ogundana, Ruth Oluwaseun Obaado, Jolly Amoche Adole, Imonikhe Kennedy Kio, Folefac Agnes Njeandoh, Alexandra Tuttle, Walter O. Oguta, Jonathan Greene, Aminata Koroma, Joseph Kanu, Mamadou Aliou Barry, Aboubacry Gaye, Andy Mahine Diouf, Christine Hughes, Joshua I. Levy, Alhaji N’jai, Moussa Moise Diagne, Dolo Nosamiefan, George Ameh, John Klena, Monique A. Foster, Abebaw Kebede, Collins Tanui, Boubacar Diallo, Anise Happi, Sofonias Tessema, Abdourahmane Sow, Yenew Kebede, Isatta Wurie, James Squire, Doris Harding, Zikan Koroma, Mohamed Boie Jalloh, Amadou Alpha Sall, Kristian G. Andersen, Andrew Rambaut, Mohamed Alex Vandi, Ibrahima Socé Fall, Pardis Sabeti, Christian Happi, Foday Sahr, Donald S. Grant

• May 12, 2026

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

• by Kathryn Wighton

• April 21, 2026

• 2 min